Advertisement

Liver Diseases pp 661-666 | Cite as

Systemic Therapy of Advanced Liver Cancer

  • Matthias OckerEmail author
Chapter

Abstract

Advanced liver cancer (HCC) is a global unmet medical need with only limited treatment options esp. for advanced disease stages. While chemotherapy was unsatisfying and locoregional therapies or surgery are limited to early disease stages, the development of small molecule kinase inhibitors has opened the door for new treatment approaches. The molecular profiling of HCC has identified molecule subtypes but is still limited due to numerous different underlying etiologies and the varying degree of chronic inflammation. Larger biomarker studies and mandatory biopsies are thus needed to find potential oncogenic drivers in HCC. Recently, immune checkpoint inhibitors were also investigated in HCC as single agents or in combination with chemotherapy, targeted therapy or locoregional therapy and have shown promising results in initial clinical studies. Here, the current treatment landscape of advanced HCC is summarized with a focus on immunotherapy trials.

Keywords

Hepatocellular carcinoma Liver cancer Clinical trials Targeted therapy Immunotherapy Immune checkpoint inhibitors Biomarkers 

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.Google Scholar
  2. 2.
    Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139(7):1534–45.CrossRefGoogle Scholar
  3. 3.
    Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–94.CrossRefGoogle Scholar
  4. 4.
    Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16(1):149.CrossRefGoogle Scholar
  5. 5.
    Gosalia AJ, Martin P, Jones PD. Advances and future directions in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2017;13(7):398–410.Google Scholar
  6. 6.
    Eatrides J, Wang E, Kothari N, Kim R. Role of systemic therapy and future directions for hepatocellular carcinoma. Cancer Control. 2017;24(3):1073274817729243.CrossRefGoogle Scholar
  7. 7.
    Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67(2):380–8.CrossRefGoogle Scholar
  8. 8.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.Google Scholar
  9. 9.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.CrossRefGoogle Scholar
  10. 10.
    Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.Google Scholar
  11. 11.
    Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163.CrossRefGoogle Scholar
  12. 12.
    Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–34.CrossRefGoogle Scholar
  13. 13.
    Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52(4):512–9.CrossRefGoogle Scholar
  14. 14.
    Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55.CrossRefGoogle Scholar
  15. 15.
    Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology. 2017;93(Suppl 1):135–46.CrossRefGoogle Scholar
  16. 16.
    Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib (C) versus Placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol. 2018;36(Suppl 4S):207.CrossRefGoogle Scholar
  17. 17.
    Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154–60.CrossRefGoogle Scholar
  18. 18.
    Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66.CrossRefGoogle Scholar
  19. 19.
    Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64(5):1090–8.CrossRefGoogle Scholar
  20. 20.
    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–54.CrossRefGoogle Scholar
  21. 21.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefGoogle Scholar
  22. 22.
    Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408–24.CrossRefGoogle Scholar
  23. 23.
    Elsegood CL, Tirnitz-Parker JE, Olynyk JK, Yeoh GC. Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clin Transl Immunol. 2017;6(11):e161.CrossRefGoogle Scholar
  24. 24.
    Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006;12(23):3716–21.CrossRefGoogle Scholar
  25. 25.
    Behm B, Di Fazio P, Michl P, Neureiter D, Kemmerling R, Hahn EG, et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut. 2016;65(1):134–43.CrossRefGoogle Scholar
  26. 26.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.CrossRefGoogle Scholar
  27. 27.
    Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–93.CrossRefGoogle Scholar
  28. 28.
    Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 Update. Oncology. 2017;93(Suppl 1):147–59.CrossRefGoogle Scholar
  29. 29.
    Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–8.CrossRefGoogle Scholar
  30. 30.
    Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–51.CrossRefGoogle Scholar
  31. 31.
    El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.CrossRefGoogle Scholar
  32. 32.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.CrossRefGoogle Scholar
  33. 33.
    Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.CrossRefGoogle Scholar
  34. 34.
    Kelley RK, Abou-Alfa GK, Bendell JC, Kim TY, Borad MJ, Yong WP. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol. 2017;35(15 Suppl):4073.CrossRefGoogle Scholar
  35. 35.
    Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67(5):999–1008.CrossRefGoogle Scholar
  36. 36.
    Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, et al. A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. Semin Cancer Biol. 2018;52:158.CrossRefGoogle Scholar
  37. 37.
    Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.CrossRefGoogle Scholar
  38. 38.
    Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018;69:237.CrossRefGoogle Scholar
  39. 39.
    EASL-EORTC. clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Translational Medicine OncologyBayer AGBerlinGermany
  2. 2.Charité University Medicine BerlinBerlinGermany

Personalised recommendations